The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...

Discover how mRNA vaccines could revolutionize medicine by targeting 9 major diseases. Learn about breakthrough treatments ...

The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has singled it out for scrutiny, clouding its prospects.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Scientists have long-known that mRNA could hold the key to developing much-needed vaccines. The covid pandemic proved them right, spurring a boom in mRNA-based vaccine research that could soon ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health ...